Pharmion - Best Pharma Stocks of 2007

Company: Pharmion
Starting stock price: $26.7
Ending stock price: $62.68
Percent Change: 135%

Details: Pharmion acquires, develops and commercializes hematology and oncology products. In November 2007, Celgene bought Pharmion for $2.9 billion--11 times Pharmion's annual revenue and a 46 percent premium for its shares. Pharmion sells Vidaza and Thalomid and is working on a late-stage therapy for small-cell lung cancer and a mid-stage oncology drug MGCD0103.

More News:
Celgene goes global with $2.9B Pharmion buyout. Report
Pharmion nets cancer therapy in Cabrellis buyout. Report
Pharmion signs $270M licensing deal for GPC's satraplatin. Report

Pharmion - Best Pharma Stocks of 2007

Suggested Articles

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.

House Democrats passed Pelosi's drug pricing bill, named after the late Rep. Elijah Cummings, in a mostly party-line vote Thursday.